What is MXCT's current stock price?

MXCT (MaxCyte, Inc.) is currently trading at $1.04 with a market cap of $111.4M.

What sector is MaxCyte, Inc. in?

MaxCyte, Inc. (MXCT) operates in the Healthcare sector, specifically in the Medical - Devices industry.

Is MXCT a good stock to buy?

Analysts have a Buy consensus on MXCT with a price target of $6.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

MXCT MaxCyte, Inc.

Healthcare

$1.04-1.89%ClosedMarket Cap: $111.4M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.66

P/S

3.45

EV/EBITDA

-3.17

DCF Value

$-3.05

FCF Yield

-26.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

80.7%

Operating Margin

-119.7%

Net Margin

-121.2%

ROE

-22.0%

ROA

-20.1%

ROIC

-20.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$9.7M	$-4.8M	$—
Q4 null	$7.3M	$-9.6M	$—
FY null	$33.0M	$-44.6M	$—
Q3 null	$6.8M	$-12.4M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$6.00

Target (Median)

$6.00

Target Range

$6.00 - $6.00

0 Strong Buy5 Buy2 Hold0 Sell0 Strong Sell

Craig-HallumBuy

2026-03-25

BTIGNeutral

2025-08-11

William BlairMarket Perform

2025-08-07

Trading Activity

Insider Trades

View All

Ahuja Parmeetofficer: Chief Financial Officer

SellFri Apr 17

Ahuja Parmeetofficer: Chief Financial Officer

SellFri Apr 10

Ahuja Parmeet

SellFri Apr 10

Masoud Maherdirector, officer: President and CEO

SellTue Mar 31

Masoud Maherdirector, officer: President and CEO

SellTue Mar 31

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

Exchange

—

Beta

1.57

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

Peers

AVR

PRE